Previsioni di mercato degli adiuvanti per vaccini umani nell\'Asia del Pacifico fino al 2030 - Analisi regionale - per tipo (adiuvante particolato, adiuvante in emulsione, adiuvante combinato e altri), applicazione (influenza, epatite, virus del papilloma umano (HPV) e altri) e utente finale ( Aziende farmaceutiche e biotecnologiche, CMO e CRO e altri)
L\'industria farmaceutica in crescita stimola il mercato degli adiuvanti per i vaccini umani nell\'Asia Pacifico.
Si prevede che l\'industria farmaceutica in espansione influenzerà positivamente la domanda di adiuvanti poiché possono migliorare l’efficacia e la sicurezza dei vaccini. La crescente attenzione dell’industria farmaceutica verso le malattie infettive, il cancro e le malattie autoimmuni fornisce una piattaforma per lo sviluppo di vaccini e adiuvanti personalizzati mirati a queste specifiche aree patologiche. Ciò offre ai produttori di adiuvanti l’opportunità di sviluppare adiuvanti specializzati per migliorare la risposta immunitaria ai vaccini per queste malattie. Secondo l’EFPIA, le industrie farmaceutiche brasiliana, cinese e indiana sono cresciute rispettivamente dell’11,7%, 6,7% e 11,8% nel periodo 2016-2021, rispetto ai cinque principali mercati dell’Unione Europea e al mercato statunitense, che hanno registrato un crescita media del mercato rispettivamente del 5,8% e del 5,6%. Inoltre, secondo l’India Brand Equity Foundation (IBEF), l’India è un attore importante e in crescita nel settore farmaceutico globale. Il paese è il più grande commerciante al mondo di farmaci generici, rappresentando quasi il 20% della fornitura mondiale in volume. Fornisce circa il 50% della domanda globale di vaccinazioni. L’industria farmaceutica nazionale comprende una rete di 3.000 aziende farmaceutiche e circa 10.500 unità produttive. Secondo i dati ufficiali del governo indiano, il settore farmaceutico indiano vale quasi 50 miliardi di dollari, di cui oltre 25 miliardi provengono dalle esportazioni. L’India rappresenta circa il 20% delle esportazioni mondiali di medicinali generici. Inoltre, il Giappone è uno dei mercati farmaceutici più grandi del mondo. Secondo le statistiche annuali sulla produzione farmaceutica del Ministero della salute, del lavoro e del welfare (MHLW), il mercato giapponese dei prodotti farmaceutici con e senza prescrizione medica nel 2020 ammontava a 107 miliardi di dollari. Mentre il settore continua ad evolversi e a innovarsi, vi è una crescente domanda di adiuvanti in grado di supportare lo sviluppo di vaccini personalizzati, determinando una crescita e investimenti significativi nel mercato degli adiuvanti per vaccini umani nell’Asia del Pacifico. Pertanto, la crescita dell’industria farmaceutica a livello mondiale creerà probabilmente opportunità di crescita redditizie per il mercato degli adiuvanti dei vaccini umani nell’Asia del Pacifico nei prossimi anni.
Panoramica del mercato degli adiuvanti per vaccini umani nell\'Asia Pacifico
La Cina ha investito molto nei suoi settori sanitario e farmaceutico, con l\'obiettivo di rafforzare le capacità di produzione, ricerca e sviluppo nazionali. Questo focus strategico ha posizionato il Paese come attore chiave nel mercato degli adiuvanti per vaccini umani nell’Asia del Pacifico. Inoltre, la Cina è tra i paesi più densamente popolati al mondo; la popolazione attuale è di ~ 1,41 miliardi. Secondo l’ultimo studio Global Burden of Disease (GBD) pubblicato nell’ottobre 2020, la popolazione del paese è soggetta a varie malattie infettive, croniche e acute.
Si prevede che un aumento della prevalenza delle malattie infettive alimenterà la domanda di vaccinazioni. Secondo un rapporto del Centro informazioni ICO/IARC su HPV e cancro nel 2023, la Cina ha una popolazione di 582,4 milioni di donne di età pari o superiore a 15 anni che sono a rischio di sviluppare cancro cervicale correlato all’HPV. Si stima che circa il 3,8% delle donne in Cina nella popolazione generale presentino un’infezione cervicale da HPV-16/18 in un dato momento, e il 69,1% dei tumori cervicali invasivi sono attribuiti agli HPV 16 o 18. Pertanto, il numero crescente di pazienti e Si prevede inoltre che la crescente domanda di vaccini per il trattamento stimolerà la crescita del mercato degli adiuvanti dei vaccini umani nell’Asia del Pacifico.
Entrate e previsioni del mercato degli adiuvanti per vaccini umani nell\'Asia Pacifico fino al 2030 (milioni di dollari)
Segmentazione del mercato degli adiuvanti per vaccini umani nell\'Asia Pacifico
Il mercato degli adiuvanti per vaccini umani nell\'Asia Pacifico è classificato in tipo, applicazione, utente finale e paese.
In base alla tipologia, il mercato degli adiuvanti per vaccini umani nell\'Asia del Pacifico è segmentato adiuvante particolato, adiuvante in emulsione, adiuvante combinato e altri. Il segmento degli adiuvanti del particolato ha detenuto la quota di mercato maggiore nel 2022.
In termini di applicazione, il mercato degli adiuvanti per vaccini umani nell\'Asia del Pacifico è classificato in influenza, epatite, virus del papilloma umano (HPV) e altri. Il segmento dell\'influenza ha detenuto la quota di mercato maggiore nel 2022.
In base all\'utente finale, il mercato degli adiuvanti per vaccini umani nell\'Asia Pacifico è segmentato in aziende farmaceutiche e biotecnologiche, CMO e CRO e altri. Il segmento delle aziende farmaceutiche e biotecnologiche ha detenuto la quota di mercato maggiore nel 2022.
Per paese, il mercato degli adiuvanti per vaccini umani nell\'area Asia Pacifico è segmentato in Giappone, Cina, India, Australia, Corea del Sud e resto dell\'Asia Pacifico . Nel 2022, la Cina ha dominato la quota di mercato degli adiuvanti per vaccini umani nella regione Asia-Pacifico.
Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Hawaii Biotech Inc, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA e SPI Pharma Inc è una delle aziende leader che operano nel mercato degli adiuvanti per vaccini umani nell\'Asia del Pacifico.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Human Vaccine Adjuvants Market - Key Market Dynamics
4.1 Asia Pacific Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases
4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:
5. Human Vaccine Adjuvants Market - Asia Pacific Market Analysis
5.1 Asia Pacific Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Asia Pacific Human Vaccine Adjuvants Market Forecast Analysis
6. Asia Pacific Human Vaccine Adjuvants Market Analysis - by Type
6.1 Particulate Adjuvant
6.1.1 Overview
6.1.2 Particulate Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
6.2.1 Overview
6.2.2 Emulsion Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
6.3.1 Overview
6.3.2 Combination Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
6.4.1 Overview
6.4.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Human Vaccine Adjuvants Market Analysis - by Application
7.1 Influenza
7.1.1 Overview
7.1.2 Influenza: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
7.2.1 Overview
7.2.2 Hepatitis: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
7.3.1 Overview
7.3.2 Human papilloma virus (HPV): Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Human Vaccine Adjuvants Market Analysis - by End User
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Overview
8.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
8.2.1 Overview
8.2.2 CMOs and CROs: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Human Vaccine Adjuvants Market - Country Analysis
9.1 Asia Pacific
9.1.1 Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
9.1.1.1 China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 China Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.1.2 China Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.1.3 China Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.2 Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 Japan Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.2.2 Japan Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.2.3 Japan Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.3 India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 India Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.3.2 India Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.3.3 India Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.4 Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.1 Australia Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.4.2 Australia Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.4.3 Australia Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.5 South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.5.1 South Korea Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.5.2 South Korea Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.5.3 South Korea Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.6 Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.6.1 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.6.2 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.6.3 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by End User
10. Industry Landscape
10.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Dynavax Technologies Corp
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 CSL Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Seppic SA
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 SPI Pharma Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Hawaii Biotech Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Croda International Plc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Novavax Inc
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Phibro Animal Health Corp
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
List of Tables
Table 1. Asia Pacific Human Vaccine Adjuvants Market Segmentation
Table 2. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 16. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 17. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 18. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 19. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 20. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 21. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 23. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 24. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 25. Glossary of Terms, Human Vaccine Adjuvants Market
List of Figures
Figure 1. Asia Pacific Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Asia Pacific Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. Asia Pacific Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Asia Pacific Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human Papilloma Virus (HPV): Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Asia Pacific Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 23. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 24. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 25. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
1. Croda International Plc
2. CSL Ltd
3. Dynavax Technologies Corp
4. Hawaii Biotech Inc
5. Novartis AG
6. Novavax Inc
7. Phibro Animal Health Corp
8. Seppic SA
9. SPI Pharma Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific human vaccine adjuvants market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific human vaccine adjuvants market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.